CIR Biopharma (Shanghai) Co., Ltd. has a senior R & D team, the core management has more than 10 years of experience working in pharmaceutical companies and/or CROs. The company unites with top research teams in China, such as Central South University, Ocean University of China, Fudan University, Hunan Cancer Hospital, etc. We focus on the technical needs of our customers' innovative projects, and actively lay out the differentiated animal models to provide high quality services to our current and potential customers. Our ultimate goal is to help our customers shorten the cycle of drug development, reduce R&D costs, and increase the success rate.
The team has rich experience in the development of technology platforms, and has collaborated with more than 20 medical institutions. We have successfully developed more than 10 types of in vivo PDX models, tumor cell lines, organoids and other products, by focusing on different types of tumors.
The service platform covers in vivo and in vitro pharmacodynamics, pharmacokinetics, Non-GLP toxicology studies, etc. The team has developed 200+ CDX models, 300+ PDX models and 50+ autoimmune and inflammatory models, and metabolic disease models. The team has established a sound quality control system to ensure the authenticity, accuracy, integrity, traceability of research data, and the timeliness of delivery. Among them, the pharmacodynamic services such as tumor pharmacological models (syngeneic model, CDX model, PDX model, orthotopic tumor model, tumor metastasis model), autoimmune and inflammatory animal models, humanized models, metabolic disease models are the advantageous technologies of the team. Our rich experiences within the above areas will efficiently assist our partners in the advancement of the new drug R&D projects.
